This website uses cookies to ensure that we give you the best experience on our website. Click here for more information.

ok

Terms of Use

The information contained in this site is for healthcare professionals only.

I am not a healthcare professional I confirm to be a healthcare professional
Osteoporosis in men

Prolia® (denosumab) for osteoporosis in men 

Male osteoporosis may occur as a result of aging and lowered testosterone levels or in men with prostate cancer receiving hormone ablation. Fracture risk is higher in these men as a result of bone loss. Osteoporosis treatment with Prolia® (denosumab) reduces the risk of vertebral fractures in men with prostate cancer receiving hormone ablation therapy and increases bone density. It is important that men on Prolia® (denosumab) therapy have adequate calcium and vitamin D intake.

Studies have shown that Prolia® (denosumab) effectively lowers vertebral fracture risk in male osteoporosis 

For the treatment of osteoporosis in men, Prolia® (denosumab) has been compared with placebo in one main study involving 242 men with osteoporosis. The primary endpoint was the change in bone density in the lumbar spine. Prolia® (denosumab) has also been studied in 1,468 men receiving treatment for prostate cancer who were at an increased risk of fracture. Efficacy was clearly demonstrated. Despite a higher average body weight in men compared to women (mean 85.2 vs. 69.8 kg), no notable differences in exposure have been noted. 

The main measure of the efficacy of Prolia® (denosumab) was the change in bone density in the lumbar spine